about
Rodent models of diabetic nephropathy: their utility and limitationsThe use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY).Regulating Autophagy as a Therapeutic Target for Diabetic Nephropathy.Practical Approach to Initiating SGLT2 Inhibitors in Type 2 DiabetesInterleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation.The ZDSD rat: a novel model of diabetic nephropathy.Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.Effect of Empagliflozin on Tacrolimus-Induced Pancreas Islet Dysfunction and Renal Injury.Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia.Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.Development of hyperkalemia following treatment with dapagliflozin (DAPA) in a patient with type 2 diabetes after bilateral adrenalectomy.Proximal Tubular Secretory Clearance: A Neglected Partner of Kidney Function.Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats.Mechanisms of Aerobic Exercise Impairment in Diabetes: A Narrative Review.A Low-Protein Diet for Diabetic Kidney Disease: Its Effect and Molecular Mechanism, an Approach from Animal Studies.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathyNewer Perspectives of Mechanisms for Euglycemic Diabetic KetoacidosisEfficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
P2860
Q28073885-257E5B61-E760-49CD-8EF1-5D489E1E742FQ38870752-95CA04E4-1FD8-4148-BFD4-F3E17A83C98CQ39160771-4F8769E0-A0BA-433F-824B-2472923B24F1Q39255188-EDC1FC55-61BD-4587-BCDA-EE885A5BD047Q39259711-4CD7BC10-E4F3-4B16-B5AB-DFA7DB4B2C77Q39358954-D453CC5C-C2A6-4111-AF65-967F96D401EDQ39443326-24DFD60C-04CE-4962-A1B6-26D282069512Q41335256-7AFC6304-0A46-4367-8357-E46F4EA168A6Q41965910-A0AABAFF-7E4B-4FD3-B757-C44B9C80BA93Q42206175-0734E014-5F70-4FAC-895E-6BC6E87A70CEQ46380921-BA2D73EC-56B0-4A88-96B9-61F16A0EE3C0Q47342428-932C9BDF-9C65-45EC-9C7A-4749EFDB962AQ47635939-382B616C-A4C1-4C5A-8DBA-C15030AA1596Q47915074-AE62419F-BC80-4E16-8CB8-B7D1BA34CF50Q48263840-0B13363E-5CBD-49A4-AFCB-5A6BEE87CBC9Q48266508-1924D874-D82D-49C2-9ACD-1137E0D9CA6CQ48291217-C516017E-3A11-4987-AEEF-B77B26169BACQ50036950-6F8EAF6C-2A42-4DF9-93A3-54BEDA098964Q52680882-8AD08905-0848-452F-B706-DE72019C1E2AQ53503168-4CC5DD01-BEA6-406E-874F-69E57E22CEF9Q53688738-F6BDE80D-BB9A-482B-80DC-DAD0C07CD12BQ54317838-D31A3F66-6091-42B4-BE3D-A668C04ED307Q55053753-9101F5D3-3E2F-4528-8345-1EFFB0EDB407Q55432730-5C7A08CA-7680-4689-B294-7D2B44B7266BQ55476982-C8B489D1-C5CB-4769-B6C4-BD1868361375Q57153398-0C11DB00-7B14-4552-90CE-42FEA6A1C4B0Q58123825-6A1560E8-A1AE-40D0-81E4-1EFEEBE3EA5AQ58456988-C0096701-FA5E-47C3-A7FC-FEF8ECAA5521
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
SGLT2 Inhibitors and the Diabetic Kidney.
@en
SGLT2 Inhibitors and the Diabetic Kidney.
@nl
type
label
SGLT2 Inhibitors and the Diabetic Kidney.
@en
SGLT2 Inhibitors and the Diabetic Kidney.
@nl
prefLabel
SGLT2 Inhibitors and the Diabetic Kidney.
@en
SGLT2 Inhibitors and the Diabetic Kidney.
@nl
P2093
P356
P1433
P1476
SGLT2 Inhibitors and the Diabetic Kidney.
@en
P2093
Alberto Zambon
Marco Rossato
Paola Fioretto
Roberto Vettor
P304
P356
10.2337/DCS15-3006
P407
P478
39 Suppl 2
P50
P577
2016-08-01T00:00:00Z